2-(4-(Aminomethyl)phenoxy)-N,N-Dimethylethanamine

20059-73-8

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is market-o‌riented and realizes industrial development through R&a¶mp;D innovation and technology transformation.

key word:

Pharmaceutical innovative

Category:

Related

Product Description

Integrity, innovation, cooperation, sharing, win-win

The company integrates multiple resources and strives to build a large health industry∞ finance platform company integrating pharmaceutical, intelligent medical, b∑io pharmaceutical R&D, industrial production and sales.

The chemical reactions involved in the existing products include Foucault reaction, nitra÷tion reaction, sulfonation reaction, hydrogenation reaction, fluorination reaction, chlorination☆ reaction, bromination reaction, diazotization reaction, format reaction, etc.

Related products

Sitagliptin Phosphate Monohydrate

Sitagliptin phosphate is a dipeptidyl peptidase-4 (DPP4) inhibitor dev​eloped by Merck. In October 2006, Sitagliptin phosphate Januvia was approved by FDA♥ as the first DPP4 inhibitor for the treatment of typ e ⅱ diabetes mellitus. The characteristics of this druφg are that it can stimulate insulin secretion while reducing hunger without causing weight gainλ. Hypoglycemia and edema will not occur, and it is suitable for diabetic patients with poo$r blood glucose control and frequent hypoglycemia.

Sumatriptan Succinate

Medication for migraine

Vildagliptin

Chenglian Pharmaceutical is an innovative high-tech phaαrmaceutical enterprise that is market-oriented and realizes₽ industrial development through R&D innovation and te₩chnology transformation.

Ketoprofen

The non-steroidal anti-inflammatory drug ketoprofen is one of the most important prodΩucts for the treatment of arthritis. It is well tole₽rated and has a low incidence of side effects

Pranlukast

Pranlukast, developed by Ono, is one of the three major leukotriene •receptor antagonists. In clinical application, it has good therapeutic effectλ on atopic asthma and other types of bronchial asthma, and the market prospect is huge. Inα the major category of asthma drugs, leukotriene receptor σantagonists have the fastest growing market share.

Avanafil

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is market-or∏iented and realizes industrial development through R&D innovation an♠d technology transformation.

Donepezil HCL

Treatment of mild to moderate Alzheimer's syndrome. It is th×e second drug approved by FDA for Alzheimer's disease in the United S↕tates. Its treatment reaches the target dose and has low toxic and side effects. It has bee n widely recognized by our medical community, and good tolerance is its biggest advanta•ge. In October 1999, Donepezil was launched in China under< the trade name "Aricept", which is the main chemical dr÷ug against Alzheimer's disease. At present, CFDA has approved a  number of domestic enterprises to produce donepezil prepara↔tions, the main dosage forms are tablets, capsules, dispersive tablets, oral disint♠egrating tablets.

Almotriptan

Migraine medication for adolescents

Apixaban

English name Apixaban Trade name ELIQUIS, tablet: Api↔xaban (Eliquis, Bristol-Myers Squibb/Pfizer), a direct oral factor Xa inhibitor,‌ was approved for use in the 27 EU member states. The world's first drug approved to prevent venousα thromboembolism (VTE) in adult patients undergoing elective hip or knee re≠placement. From June 2019 to June 2020, the annual  sales of apixaban products overseas reached about $15.4 billion, with a y≠ear-on-year growth of nearly 32%, and the API consumption reached about 23,960 kg,← with a year-on-year growth of about 28%. Compared≠ with its main competitor, Rivaroxaban, the drug's annua§l overseas sales are about $4.5 billion higher.

Lenvatinib

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise thλat is market-oriented and realizes industrial development through R&D innovatioαn and technology transformation.

Clofarabine

It is a nucleotide analogue developed by Bioenvision and manufa ctured by Genzyme. On December 29, 2004, it was approved by FDA for the treatment of refractory± or relapsed acute lymphoblastic leukemia (ALL) in children.

Upadacitinib(Scientific research)

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterp→rise that is market-oriented and realizes industrial development throβugh R&D innovation and technology transformation.

Product Consulting

Our staff will contact you within 24 hours (working days). If< you need other services, E-mail: 2880705932@qq.com

Copyright © 2022 Anhui Union Pharmaceuticals Technology Co., Ltd.

Powered by www.300.cn  | SEO